Identification of Serum Biomarker Signatures Associated with Pancreatic Cancer

Abstract

Pancreatic cancer is an aggressive disease with poor prognosis, due, in part, to the lack of disease-specific biomarkers that could afford early and accurate diagnosis. With a recombinant antibody microarray platform, targeting mainly immunoregulatory proteins, we screened sera from 148 patients with pancreatic cancer, chronic pancreatitis, autoimmune pancreatitis (AIP), and healthy controls (N). Serum biomarker signatures were derived from training cohorts and the predictive power was evaluated using independent test cohorts. The results identified serum portraits distinguishing pancreatic cancer from N [receiver operating characteristics area under the curve (AUC) of 0.95], chronic pancreatitis (0.86), and AIP (0.99). Importantly, a 25-serum biomarker signature discriminating pancreatic cancer from the combined group of N, chronic pancreatitis, and AIP was determined. This signature exhibited a high diagnostic potential (AUC of 0.88). In summary, we present the first prevalidated, multiplexed serum biomarker signature for diagnosis of pancreatic cancer that may improve diagnosis and prevention in premalignant diseases and in screening of high-risk individuals. Cancer Res; 72(10);

Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls

“…A panel of markers reflecting different patho-physiological processes involved in different pancreatic diseases will almost certainly be required for diagnosis, prognosis and assessment of the efficacy of interventions. The collagen turnover biomarkers may potentially combine with other tools (such as a recently described 25 protein platform based on the role of the immune system in PDAC [38]) and add additional information that may improve PC outcome.…”

Biomarkers of Inflammatory Bowel Disease

“…Wingren et al pointed out that the individual biomarkers that have been identified for pancreatic cancer [e.g., C-reactive protein (CRP), haptoglobin, IGF-binding protein (IGFBP)-1 and CA 19-9] all lack specificity, as they are elevated in both nonmalignant conditions (e.g., pancreatitis and acute cholangitis) and other gastrointestinal cancers (e.g., gastric cancer and colorectal cancer) (59). Thus, the authors set out to identify a serum protein biomarker signature.…”

Predicting Antidisease Immunity Using Proteome Arrays and Sera from Children Naturally Exposed to Malaria

“…Typically these methods focus on selecting a subset of features (e.g. biomarkers) that maximize predictive accuracy, such as support vector machine (SVM) with backward feature selection (73) or partial area under the curve (AUC) (74), algorithms. However, recent research using simulated data implies that for biomarker discovery the best feature-ranking methods also estimate false discovery rates, which are not calculated by SVM and AUC algorithms.…”